Preventing re-infections, more variants, and a prolonged pandemic By Daniel R. Lucey MD, MPH, FIDSA Emerging data since mid-January from South Africa and northern Brazil signal it is imperative to develop multivalent COVID vaccines (bivalent, trivalent, quadrivalent) for international use. An alternative strategy that is unlikely to succeed internationally is monovalent “booster” vaccines containing either […]
HIV
The following is a guest post by Maureen Luba Milambe, African Regional Advocacy Advisor, AVAC On Tuesday (June 8), the UN General Assembly voted overwhelmingly to […]
Tuberculosis
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
Research & Development
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
Policy
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]